Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

INP-Guided Network Pharmacology Discloses Multi-Target Therapeutic Strategy Against Cytokine and IgE Storms in the SARS-CoV-2 NB.1.8.1 Variant

Manikyam et al., Research Square, doi:10.21203/rs.3.rs-6819274/v1, Jun 2025
https://c19early.org/manikyam.html
Quercetin for COVID-19
27th treatment shown to reduce risk in July 2021, now with p = 0.002 from 12 studies.
No treatment is 100% effective. Protocols combine treatments.
5,900+ studies for 172 treatments. c19early.org
Computational modeling study presenting a multi-target therapeutic approach against the SARS-CoV-2 NB.1.8.1 variant using Intrinsic Network Pharmacology (INP) and network pharmacology tools. The researchers identified ZINC000014930714, a triterpenoid glycoside, and its natural alternative glycyrrhizin as potential fusion inhibitors targeting the HR1 domain of the spike protein, showing 90% and 85% inhibition in pseudovirus assays, respectively. They proposed a combination therapy of fusion inhibitors with camostat (TMPRSS2 inhibitor) and baricitinib (JAK/STAT inhibitor) delivered via nano-liposomal inhalation to simultaneously target viral entry and host inflammatory responses. Authors suggest this approach could suppress both cytokine and IgE-mediated inflammatory pathways.
83 preclinical studies support the efficacy of quercetin for COVID-19:
In Silico studies predict inhibition of SARS-CoV-2, or minimization of side effects, with quercetin or metabolites via binding to the spikeA,7,8,14,15,27,29,30,32,35,43,44,46,47,69 (and specifically the receptor binding domainB,4), MproC,3,4,7,8,12,14,16,18,20,22,23,25,28,29,32,35,39,41-43,47-50,66, RNA-dependent RNA polymeraseD,4,6-8,14,37, PLproE,8,42,50, ACE2F,27,28,32,33,42,46, TMPRSS2G,27, nucleocapsidH,8, helicaseI,8,34,39, endoribonucleaseJ,44, NSP16/10K,11, cathepsin LL,31, Wnt-3M,27, FZDN,27, LRP6O,27, ezrinP,45, ADRPQ,43, NRP1R,46, EP300S,21, PTGS2T,28, HSP90AA1U,21,28, matrix metalloproteinase 9V,36, IL-6W,26,40, IL-10X,26, VEGFAY,40, and RELAZ,40 proteins, and inhibition of spike-ACE2 interactionAA,5. In Vitro studies demonstrate inhibition of the MproC,20,52,57,65 protein, and inhibition of spike-ACE2 interactionAA,53. In Vitro studies demonstrate efficacy in Calu-3AB,56, A549AC,26, HEK293-ACE2+AD,64, Huh-7AE,30, Caco-2AF,55, Vero E6AG,24,47,55, mTECAH,58, RAW264.7AI,58, and HLMECAJ,5 cells. Animal studies demonstrate efficacy in K18-hACE2 miceAK,61, db/db miceAL,58,68, BALB/c miceAM,67, and rats24. Quercetin reduced proinflammatory cytokines and protected lung and kidney tissue against LPS-induced damage in mice67, inhibits LPS-induced cytokine storm by modulating key inflammatory and antioxidant pathways in macrophages10, may block ACE2-spike interaction and NLRP3 inflammasome, limiting viral entry and inflammation1, and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity60.
Study covers quercetin, camostat, and nafamostat.
a. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.
b. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.
c. The main protease or Mpro, also known as 3CLpro or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting Mpro disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.
d. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.
e. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.
f. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.
g. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.
h. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.
i. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.
j. The endoribonuclease, also known as NendoU or nsp15, cleaves specific sequences in viral RNA which may help the virus evade detection by the host immune system. Inhibition may hinder the virus's ability to mask itself from the immune system, facilitating a stronger immune response.
k. The NSP16/10 complex consists of non-structural proteins 16 and 10, forming a 2'-O-methyltransferase that modifies the viral RNA cap structure. This modification helps the virus evade host immune detection by mimicking host mRNA, making NSP16/10 a promising antiviral target.
l. Cathepsin L is a host lysosomal cysteine protease that can prime the spike protein through an alternative pathway when TMPRSS2 is unavailable. Dual targeting of cathepsin L and TMPRSS2 may maximize disruption of alternative pathways for virus entry.
m. Wingless-related integration site (Wnt) ligand 3 is a host signaling molecule that activates the Wnt signaling pathway, which is important in development, cell growth, and tissue repair. Some studies suggest that SARS-CoV-2 infection may interfere with the Wnt signaling pathway, and that Wnt3a is involved in SARS-CoV-2 entry.
n. The frizzled (FZD) receptor is a host transmembrane receptor that binds Wnt ligands, initiating the Wnt signaling cascade. FZD serves as a co-receptor, along with ACE2, in some proposed mechanisms of SARS-CoV-2 infection. The virus may take advantage of this pathway as an alternative entry route.
o. Low-density lipoprotein receptor-related protein 6 is a cell surface co-receptor essential for Wnt signaling. LRP6 acts in tandem with FZD for signal transduction and has been discussed as a potential co-receptor for SARS-CoV-2 entry.
p. The ezrin protein links the cell membrane to the cytoskeleton (the cell's internal support structure) and plays a role in cell shape, movement, adhesion, and signaling. Drugs that occupy the same spot on ezrin where the viral spike protein would bind may hindering viral attachment, and drug binding could further stabilize ezrin, strengthening its potential natural capacity to impede viral fusion and entry.
q. The Adipocyte Differentiation-Related Protein (ADRP, also known as Perilipin 2 or PLIN2) is a lipid droplet protein regulating the storage and breakdown of fats in cells. SARS-CoV-2 may hijack the lipid handling machinery of host cells and ADRP may play a role in this process. Disrupting ADRP's interaction with the virus may hinder the virus's ability to use lipids for replication and assembly.
r. Neuropilin-1 (NRP1) is a cell surface receptor with roles in blood vessel development, nerve cell guidance, and immune responses. NRP1 may function as a co-receptor for SARS-CoV-2, facilitating viral entry into cells. Blocking NRP1 may disrupt an alternative route of viral entry.
s. EP300 (E1A Binding Protein P300) is a transcriptional coactivator involved in several cellular processes, including growth, differentiation, and apoptosis, through its acetyltransferase activity that modifies histones and non-histone proteins. EP300 facilitates viral entry into cells and upregulates inflammatory cytokine production.
t. Prostaglandin G/H synthase 2 (PTGS2, also known as COX-2) is an enzyme crucial for the production of inflammatory molecules called prostaglandins. PTGS2 plays a role in the inflammatory response that can become severe in COVID-19 and inhibitors (like some NSAIDs) may have benefits in dampening harmful inflammation, but note that prostaglandins have diverse physiological functions.
u. Heat Shock Protein 90 Alpha Family Class A Member 1 (HSP90AA1) is a chaperone protein that helps other proteins fold correctly and maintains their stability. HSP90AA1 plays roles in cell signaling, survival, and immune responses. HSP90AA1 may interact with numerous viral proteins, but note that it has diverse physiological functions.
v. Matrix metalloproteinase 9 (MMP9), also called gelatinase B, is a zinc-dependent enzyme that breaks down collagen and other components of the extracellular matrix. MMP9 levels increase in severe COVID-19. Overactive MMP9 can damage lung tissue and worsen inflammation. Inhibition of MMP9 may prevent excessive tissue damage and help regulate the inflammatory response.
w. The interleukin-6 (IL-6) pro-inflammatory cytokine (signaling molecule) has a complex role in the immune response and may trigger and perpetuate inflammation. Elevated IL-6 levels are associated with severe COVID-19 cases and cytokine storm. Anti-IL-6 therapies may be beneficial in reducing excessive inflammation in severe COVID-19 cases.
x. The interleukin-10 (IL-10) anti-inflammatory cytokine helps regulate and dampen immune responses, preventing excessive inflammation. IL-10 levels can also be elevated in severe COVID-19. IL-10 could either help control harmful inflammation or potentially contribute to immune suppression.
y. Vascular Endothelial Growth Factor A (VEGFA) promotes the growth of new blood vessels (angiogenesis) and has roles in inflammation and immune responses. VEGFA may contribute to blood vessel leakiness and excessive inflammation associated with severe COVID-19.
z. RELA is a transcription factor subunit of NF-kB and is a key regulator of inflammation, driving pro-inflammatory gene expression. SARS-CoV-2 may hijack and modulate NF-kB pathways.
aa. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.
ab. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.
ac. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.
ad. HEK293-ACE2+ is a human embryonic kidney cell line engineered for high ACE2 expression and SARS-CoV-2 susceptibility.
ae. Huh-7 cells were derived from a liver tumor (hepatoma).
af. Caco-2 cells come from a colorectal adenocarcinoma (cancer). They are valued for their ability to form a polarized cell layer with properties similar to the intestinal lining.
ag. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.
ah. mTEC is a mouse tubular epithelial cell line.
ai. RAW264.7 is a mouse macrophage cell line.
aj. HLMEC (Human Lung Microvascular Endothelial Cells) are primary endothelial cells derived from the lung microvasculature. They are used to study endothelial function, inflammation, and viral interactions, particularly in the context of lung infections such as SARS-CoV-2. HLMEC express ACE2 and are susceptible to SARS-CoV-2 infection, making them a relevant model for studying viral entry and endothelial responses in the lung.
ak. A mouse model expressing the human ACE2 receptor under the control of the K18 promoter.
al. A mouse model of obesity and severe insulin resistance leading to type 2 diabetes due to a mutation in the leptin receptor gene that impairs satiety signaling.
am. A mouse model commonly used in infectious disease and cancer research due to higher immune response and susceptibility to infection.
Manikyam et al., 5 Jun 2025, preprint, 2 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
INP-Guided Network Pharmacology Discloses Multi-Target Therapeutic Strategy Against Cytokine and IgE Storms in the SARS-CoV-2 NB.1.8.1 Variant
Hemanth Kumar Manikyam, Sunil K Joshi
doi:10.21203/rs.3.rs-6819274/v1
The continuous development of SARS-CoV-2 has given rise to the NB1.8.1 variant, which exhibits augmented pathogenicity, immune escape, and drug resistance against traditional therapeutics. The current study investigates a multi-layered systems pharmacology approach for identifying new therapeutic candidates that act on both viral entry and host-mediated in ammatory storms. By combining a seven-layer Intrinsic Network Pharmacology (INP) protocol with Network Pharmacology tools, we dissected the molecular failure network triggered by NB1.8.1, with emphasis on spike protein mutations that increase ACE2 binding, disrupt early interferon responses, and induce extreme cytokine and IgE storms. The HR1 and HR2 domain of the S2 fusion machinery was found to be a key weakness. We identi ed and con rmed a triterpenoid glycoside, ZINC000014930714, with high-a nity docking into the HR1 groove and strong pseudovirus fusion inhibition. Concurrently, we identi ed glycyrrhizin, a readily available natural saponin found in licorice, as a suitable surrogate with comparable fusion inhibition. Additional important modulators including camostat as an inhibitor of TMPRSS2, baricitinib targeting JAK and STAT signaling, sulforaphane as a Nrf2 activator, and metformin as an AMPK activator were incorporated into an inhalable nano-liposomal formulation strategy aimed at inhibiting viral propagation and resultant downstream immune storms. Network pharmacology modeling established that the indicated combination closes down several failure nodes in the INP layers. Our research offers a system-wide approach that not only reveals timely antiviral candidates against NB1.8.1 but also provides an adaptive platform for quick transition to emerging SARS-CoV-2 variants.
References
Acharya, Ghosh, Kumar, NATURE'S RESPONSE TO INFLUENZA: A HIGH THROUGHPUT SCREENING STRATEGY OF AYURVEDIC MEDICINAL PHYTOCHEMICALS, International Journal of Pharmaceutical Sciences and Research
Alegría-Arcos, Network Pharmacology Reveals Multitarget Mechanism of Action of Drugs to Be Repurposed for COVID-19, Frontiers in Pharmacology, doi:10.3389/fphar.2022.952192
Arora, Spike Mutations in SARS-CoV-2 Omicron Variant Modulate Virus Entry and Sensitivity to Neutralizing Antibodies, Nature Communications, doi:10.1038/s41467-022-29219-2
Beigel, Remdesivir for the Treatment of Covid-19 -Final Report, New England Journal of Medicine, doi:10.1056/NEJMoa2007764
Fuhr, Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the 'Cocktail' Approach, Clinical Pharmacology & Therapeutics, doi:10.1038/sj.clpt.6100052
Gordon, A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing, Nature, doi:10.1038/s41586-020-2286-9
Guo, Yu, Liu, Jian, Yang et al., None, doi:10.1101/2025.04.30.651462
Harvey, SARS-CoV-2 Variants, Spike Mutations and Immune Escape, Nature Reviews Microbiology, doi:10.1038/s41579-021-00573-0
Hoffmann, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Jackson, Functional Importance of the D614G Mutation in the SARS-CoV-2 Spike Protein, Biochemical and Biophysical Research Communications, doi:10.1016/j.bbrc.2020.10.109
Kalil, Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2031994
Karim, Karim, New SARS-CoV-2 Variants-Clinical, Public Health, and Vaccine Implications, New England Journal of Medicine, doi:10.1056/NEJMc2100362
Korber, Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus, Cell, doi:10.1016/j.cell.2020.06.043
Kumar Manikyam, Hemanth, Computational studies on Gene Ontology for Molecular functions, Cellular component and Biological process of SARS-CoV-2 targeted proteins
Liu, The N501Y Spike Substitution Enhances SARS-CoV-2 Infection and Transmission, Nature, doi:10.1038/s41586-021-03461-1
Manikyam, Joshi, Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool, bioRxiv
Manikyam, Joshi, Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV), J Pharm Drug Res
Manikyam, Kumar ; Manikyam, Kumar, Joshi, Sunil et al., Ayurveda and Siddha systems polyherbal formulations to treat COVID-19 caused by SARS-CoV-2 and brief insight on application of Molecular Docking and SWISS Target prediction tools to study e cacy of active molecules, International Journal of Phytomedicine, doi:10.5138/09750185.2409
Manikyam, Kumar, High-Throughput Insilico Drug Screen against Mpox Targeted Proteins in Comparison with Repurposed Antiviral Drugs against Natural Compounds, Journal of Pharmaceutical Research International
Manikyam, Kumar, Joshi, Dammarane and Ergostane derivatives as prophylactic agents against SARS-CoV-2 host cell entry Inhibitors, J Pharmacogn Phytochem
Manikyam, Kumar, Joshi, Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of In Factors against Novel Corona Virus Infection, Acta Scienti c Pharmaceutical Sciences
Mcauley, Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in SARS-CoV-2 Spike Protein, npj Vaccines, doi:10.1038/s41541-020-00246-8
Muthuramalingam, Network Pharmacology: An E cient but Underutilized Approach in Oral, Head and Neck Cancer Therapy-A Review, Frontiers in Pharmacology, doi:10.3389/fphar.2024.1410942
Noor, Network Pharmacology Approach for Medicinal Plants: Review and Assessment, Pharmaceuticals, doi:10.3390/ph15050572
Sathian, Brijesh, Strengthening Healthcare through Academic and Industry Partnership Research, Nepal Journal of Epidemiology
Shang, Structural Basis of Receptor Recognition by SARS-CoV-2, Nature, doi:10.1038/s41586-020-2179-y
Singh, A Systematic Review of Structural and Functional Impacts of SARS-CoV-2 Spike Mutations, Cell, doi:10.1016/j.cell.2020.12.045
Tripathi, Emerging SARS-CoV-2 Variants and Their Impact on Spike Glycoprotein-Mediated Viral Entry and Immune Evasion, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2021.777378
Walls, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, doi:10.1016/j.cell.2020.02.058
Wrapp, Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation, Science, doi:10.1126/science.abb2507
Yamamoto, The Antioxidant Nrf2 Activator, Sulforaphane, Suppresses SARS-CoV-2 Entry into Human Lung Epithelial Cells, Scienti c Reports, doi:10.1038/s41598-021-99791-y
Zhai, Network Pharmacology: A Crucial Approach in Traditional Chinese Medicine Research, Chinese Medicine, doi:10.1186/s13020-024-01056-z
Zhang, SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity, Nature Communications, doi:10.1038/s41467-020-19808-4
Zhou, A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin, Nature, doi:10.1038/s41586-020-2012-7
Zhou, Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Niacin and COVID-19 as Potential Therapeutic Targets, Brie ngs in Bioinformatics, doi:10.1093/bib/bbaa373
DOI record: { "DOI": "10.21203/rs.3.rs-6819274/v1", "URL": "http://dx.doi.org/10.21203/rs.3.rs-6819274/v1", "abstract": "<title>Abstract</title>\n <p>The continuous development of SARS-CoV-2 has given rise to the NB1.8.1 variant, which exhibits augmented pathogenicity, immune escape, and drug resistance against traditional therapeutics. The current study investigates a multi-layered systems pharmacology approach for identifying new therapeutic candidates that act on both viral entry and host-mediated inflammatory storms. By combining a seven-layer Intrinsic Network Pharmacology (INP) protocol with Network Pharmacology tools, we dissected the molecular failure network triggered by NB1.8.1, with emphasis on spike protein mutations that increase ACE2 binding, disrupt early interferon responses, and induce extreme cytokine and IgE storms. The HR1 and HR2 domain of the S2 fusion machinery was found to be a key weakness. We identified and confirmed a triterpenoid glycoside, ZINC000014930714, with high-affinity docking into the HR1 groove and strong pseudovirus fusion inhibition. Concurrently, we identified glycyrrhizin, a readily available natural saponin found in licorice, as a suitable surrogate with comparable fusion inhibition. Additional important modulators including camostat as an inhibitor of TMPRSS2, baricitinib targeting JAK and STAT signaling, sulforaphane as a Nrf2 activator, and metformin as an AMPK activator were incorporated into an inhalable nano-liposomal formulation strategy aimed at inhibiting viral propagation and resultant downstream immune storms. Network pharmacology modeling established that the indicated combination closes down several failure nodes in the INP layers. Our research offers a system-wide approach that not only reveals timely antiviral candidates against NB1.8.1 but also provides an adaptive platform for quick transition to emerging SARS-CoV-2 variants.</p>", "accepted": { "date-parts": [ [ 2025, 6, 4 ] ] }, "author": [ { "ORCID": "https://orcid.org/0000-0001-5181-6323", "affiliation": [ { "name": "North East Frontier Technical University" } ], "authenticated-orcid": false, "family": "Manikyam", "given": "Hemanth kumar", "sequence": "first" }, { "affiliation": [ { "name": "University of Miami" } ], "family": "Joshi", "given": "Sunil K", "sequence": "additional" } ], "container-title": [], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2025, 6, 5 ] ], "date-time": "2025-06-05T04:55:12Z", "timestamp": 1749099312000 }, "deposited": { "date-parts": [ [ 2025, 6, 5 ] ], "date-time": "2025-06-05T04:55:14Z", "timestamp": 1749099314000 }, "group-title": "In Review", "indexed": { "date-parts": [ [ 2025, 6, 6 ] ], "date-time": "2025-06-06T04:02:38Z", "timestamp": 1749182558187, "version": "3.41.0" }, "institution": [ { "name": "Research Square" } ], "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 6, 5 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "unspecified", "delay-in-days": 0, "start": { "date-parts": [ [ 2025, 6, 5 ] ], "date-time": "2025-06-05T00:00:00Z", "timestamp": 1749081600000 } } ], "link": [ { "URL": "https://www.researchsquare.com/article/rs-6819274/v1", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://www.researchsquare.com/article/rs-6819274/v1.html", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "297", "original-title": [], "posted": { "date-parts": [ [ 2025, 6, 5 ] ] }, "prefix": "10.21203", "published": { "date-parts": [ [ 2025, 6, 5 ] ] }, "publisher": "Springer Science and Business Media LLC", "reference": [ { "author": "Manikyam HK", "key": "ref1", "unstructured": "Manikyam HK, Joshi SK (2020) J Pharm Drug Res 3(2):341–361 Epub 2020 Mar 30. PMID: 32617527; PMCID: PMC7331973. Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)", "year": "2020" }, { "DOI": "10.3126/nje.v13i2.58243", "article-title": "Strengthening Healthcare through Academic and Industry Partnership Research", "author": "Sathian B", "doi-asserted-by": "crossref", "first-page": "1264", "issue": "2", "journal-title": "Nepal J Epidemiol", "key": "ref2", "unstructured": "Sathian B et al (2023) Strengthening Healthcare through Academic and Industry Partnership Research. Nepal J Epidemiol 13(2):1264", "volume": "13", "year": "2023" }, { "article-title": "Joshi. Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool. bioRxiv", "author": "Manikyam HK", "first-page": "2020", "key": "ref3", "unstructured": "Manikyam HK, Sunil K (2020) Joshi. Computational methods to develop potential neutralizing antibody Fab region against SARS-CoV-2 as therapeutic and diagnostic tool. bioRxiv : 2020–2005", "year": "2020" }, { "article-title": "Computational studies on Gene Ontology for Molecular functions, Cellular component and Biological process of SARS-CoV-2 targeted proteins", "author": "kumar Manikyam H", "key": "ref4", "unstructured": "kumar Manikyam H (2020) Computational studies on Gene Ontology for Molecular functions, Cellular component and Biological process of SARS-CoV-2 targeted proteins", "year": "2020" }, { "DOI": "10.1101/2025.04.30.651462", "doi-asserted-by": "crossref", "key": "ref5", "unstructured": "Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1Caiwan Guo, Yuanling Yu, Jingyi Liu, Fanchong Jian, Sijie Yang, Weiliang Song, Lingling Yu, Fei Shao, Yunlong Cao bioRxiv 2025.04.30.651462; https://doi.org/10.1101/2025.04.30.651462" }, { "article-title": "Joshi. Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of Inflammatory Factors against Novel Corona Virus Infection", "author": "Manikyam H", "first-page": "2581", "issue": "5", "journal-title": "Acta Sci Pharm Sci (ISSN", "key": "ref6", "unstructured": "Manikyam H, Kumar, Sunil K (2020) Joshi. Nicotinamide, Folic Acid and Derivatives as Potent Inhibitors of Inflammatory Factors against Novel Corona Virus Infection. Acta Sci Pharm Sci (ISSN 4(5):2581–5423", "volume": "4", "year": "2020" }, { "author": "Acharya B", "first-page": "2699", "issue": "6", "journal-title": "Int J Pharm Sci Res", "key": "ref7", "unstructured": "Acharya B, Ghosh S, Hemanth Kumar M, NATURE'S RESPONSE TO INFLUENZA: A HIGH THROUGHPUT SCREENING STRATEGY OF AYURVEDIC MEDICINAL PHYTOCHEMICALS. (2016) Int J Pharm Sci Res 7(6):2699", "volume": "7", "year": "2016" }, { "article-title": "Joshi. Dammarane and Ergostane derivatives as prophylactic agents against SARS-CoV-2 host cell entry Inhibitors", "author": "Manikyam H", "first-page": "1211", "issue": "3", "journal-title": "J Pharmacogn Phytochem", "key": "ref8", "unstructured": "Manikyam H, Kumar, Sunil K (2020) Joshi. Dammarane and Ergostane derivatives as prophylactic agents against SARS-CoV-2 host cell entry Inhibitors. J Pharmacogn Phytochem 9(3):1211–1216", "volume": "9", "year": "2020" }, { "DOI": "10.9734/jpri/2024/v36i117599", "article-title": "High-Throughput Insilico Drug Screen against Mpox Targeted Proteins in Comparison with Repurposed Antiviral Drugs against Natural Compounds", "author": "Manikyam H", "doi-asserted-by": "crossref", "first-page": "41", "issue": "11", "journal-title": "J Pharm Res Int", "key": "ref9", "unstructured": "Manikyam H, Kumar et al (2024) High-Throughput Insilico Drug Screen against Mpox Targeted Proteins in Comparison with Repurposed Antiviral Drugs against Natural Compounds. J Pharm Res Int 36(11):41–52", "volume": "36", "year": "2024" }, { "author": "Manikyam HK", "key": "ref10", "unstructured": "Manikyam HK In Silico studies of Natural compounds that inhibit SARS-CoV-2 Nucleocapsid Nsp1/Nsp3 proteins mediated Viral Replication and Pathogenesis.", "volume-title": "In Silico studies of Natural compounds that inhibit SARS-CoV-2 Nucleocapsid Nsp1/Nsp3" }, { "DOI": "10.5138/09750185.2409", "article-title": "Ayurveda and Siddha systems polyherbal formulations to treat COVID-19 caused by SARS-CoV-2 and brief insight on application of Molecular Docking and SWISS Target prediction tools to study efficacy of active molecules", "author": "Manikyam HK", "doi-asserted-by": "publisher", "journal-title": "Int J Phytomedicine", "key": "ref11", "unstructured": "Manikyam HK, Joshi S, Noor A (2020) Ayurveda and Siddha systems polyherbal formulations to treat COVID-19 caused by SARS-CoV-2 and brief insight on application of Molecular Docking and SWISS Target prediction tools to study efficacy of active molecules. Int J Phytomedicine. 10.5138/09750185.2409", "year": "2020" }, { "DOI": "10.1186/s13020-024-01056-z", "author": "Zhai Y", "doi-asserted-by": "publisher", "key": "ref12", "unstructured": "Zhai Y et al (2025) Network Pharmacology: A Crucial Approach in Traditional Chinese Medicine Research. Chinese Medicine, vol. 20, no. 8. https://doi.org/10.1186/s13020-024-01056-z", "year": "2025" }, { "DOI": "10.3389/fphar.2022.952192", "article-title": "Network Pharmacology Reveals Multitarget Mechanism of Action of Drugs to Be Repurposed for COVID-19", "author": "Alegría-Arcos M", "doi-asserted-by": "publisher", "first-page": "952192", "journal-title": "Front Pharmacol", "key": "ref13", "unstructured": "Alegría-Arcos M et al (2022) Network Pharmacology Reveals Multitarget Mechanism of Action of Drugs to Be Repurposed for COVID-19. Front Pharmacol 13:952192. https://doi.org/10.3389/fphar.2022.952192", "volume": "13", "year": "2022" }, { "DOI": "10.3390/ph15050572", "author": "Noor F", "doi-asserted-by": "publisher", "key": "ref14", "unstructured": "Noor F et al (2022) Network Pharmacology Approach for Medicinal Plants: Review and Assessment. Pharmaceuticals, vol. 15, no. 5, article 572. https://doi.org/10.3390/ph15050572", "year": "2022" }, { "DOI": "10.3389/fphar.2024.1410942", "article-title": "Network Pharmacology: An Efficient but Underutilized Approach in Oral, Head and Neck Cancer Therapy—A Review", "author": "Muthuramalingam P", "doi-asserted-by": "publisher", "first-page": "1410942", "journal-title": "Front Pharmacol", "key": "ref15", "unstructured": "Muthuramalingam P et al (2024) Network Pharmacology: An Efficient but Underutilized Approach in Oral, Head and Neck Cancer Therapy—A Review. Front Pharmacol 15:1410942. https://doi.org/10.3389/fphar.2024.1410942", "volume": "15", "year": "2024" }, { "DOI": "10.1093/bib/bbaa373", "article-title": "Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Niacin and COVID-19 as Potential Therapeutic Targets", "author": "Zhou Y", "doi-asserted-by": "publisher", "first-page": "1279", "issue": "2", "journal-title": "Brief Bioinform", "key": "ref16", "unstructured": "Zhou Y et al (2021) Network Pharmacology and Bioinformatics Analyses Identify Intersection Genes of Niacin and COVID-19 as Potential Therapeutic Targets. Brief Bioinform 22(2):1279–1290. https://doi.org/10.1093/bib/bbaa373", "volume": "22", "year": "2021" }, { "DOI": "10.1056/NEJMoa2031994", "article-title": "Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19", "author": "Kalil AC", "doi-asserted-by": "publisher", "first-page": "795", "issue": "9", "journal-title": "N Engl J Med", "key": "ref17", "unstructured": "Kalil AC et al (2021) Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 384(9):795–807. https://doi.org/10.1056/NEJMoa2031994", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the Treatment of Covid-19 — Final Report", "author": "Beigel JH", "doi-asserted-by": "publisher", "first-page": "1813", "issue": "19", "journal-title": "N Engl J Med", "key": "ref18", "unstructured": "Beigel JH et al (2020) Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med 383(19):1813–1826. https://doi.org/10.1056/NEJMoa2007764", "volume": "383", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.06.043", "article-title": "Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. Cell", "author": "Korber B", "doi-asserted-by": "publisher", "first-page": "812", "issue": "4", "key": "ref19", "unstructured": "Korber B et al (2020) Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus. Cell. 182(4):812–827e19. https://doi.org/10.1016/j.cell.2020.06.043", "volume": "182", "year": "2020" }, { "DOI": "10.1038/s41467-020-19808-4", "article-title": "SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity. Nature Communications", "author": "Zhang L", "doi-asserted-by": "publisher", "first-page": "6013", "key": "ref20", "unstructured": "Zhang L et al (2020), article no. SARS-CoV-2 Spike-Protein D614G Mutation Increases Virion Spike Density and Infectivity. Nature Communications. 11:6013. https://doi.org/10.1038/s41467-020-19808-4", "volume": "11", "year": "2020" }, { "DOI": "10.1038/s41586-021-03461-1", "article-title": "The N501Y Spike Substitution Enhances SARS-CoV-2 Infection and Transmission", "author": "Liu Y", "doi-asserted-by": "publisher", "first-page": "295", "journal-title": "Nature", "key": "ref21", "unstructured": "Liu Y et al (2021) The N501Y Spike Substitution Enhances SARS-CoV-2 Infection and Transmission. Nature 593:295–299. https://doi.org/10.1038/s41586-021-03461-1", "volume": "593", "year": "2021" }, { "DOI": "10.1056/NEJMc2100362", "article-title": "New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications", "author": "Abdool Karim SS", "doi-asserted-by": "publisher", "first-page": "1866", "issue": "19", "journal-title": "N Engl J Med", "key": "ref22", "unstructured": "Abdool Karim SS (2021) New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications. N Engl J Med 384(19):1866–1868. https://doi.org/10.1056/NEJMc2100362", "volume": "384", "year": "2021" }, { "DOI": "10.1016/j.cell.2020.02.052", "author": "Hoffmann M", "doi-asserted-by": "publisher", "key": "ref23", "unstructured": "Hoffmann M et al (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, vol. 181, no. 2, pp. 271–280.e8. https://doi.org/10.1016/j.cell.2020.02.052", "year": "2020" }, { "DOI": "10.1016/j.bbrc.2020.10.109", "article-title": "Functional Importance of the D614G Mutation in the SARS-CoV-2 Spike Protein", "author": "Jackson CB", "doi-asserted-by": "publisher", "first-page": "108", "journal-title": "Biochem Biophys Res Commun", "key": "ref24", "unstructured": "Jackson CB et al (2021) Functional Importance of the D614G Mutation in the SARS-CoV-2 Spike Protein. Biochem Biophys Res Commun 538:108–115. https://doi.org/10.1016/j.bbrc.2020.10.109", "volume": "538", "year": "2021" }, { "DOI": "10.1038/s41586-020-2286-9", "article-title": "A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing", "author": "Gordon DE", "doi-asserted-by": "publisher", "first-page": "459", "journal-title": "Nature", "key": "ref25", "unstructured": "Gordon DE et al (2020) A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nature 583:459–468. https://doi.org/10.1038/s41586-020-2286-9", "volume": "583", "year": "2020" }, { "DOI": "10.1126/science.abb2507", "article-title": "Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation", "author": "Wrapp D", "doi-asserted-by": "publisher", "first-page": "1260", "issue": "6483", "journal-title": "Science", "key": "ref26", "unstructured": "Wrapp D et al (2020) Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science 367(6483):1260–1263. https://doi.org/10.1126/science.abb2507", "volume": "367", "year": "2020" }, { "DOI": "10.1038/s41586-020-2179-y", "article-title": "Structural Basis of Receptor Recognition by SARS-CoV-2", "author": "Shang J", "doi-asserted-by": "publisher", "first-page": "221", "journal-title": "Nature", "key": "ref27", "unstructured": "Shang J et al (2020) Structural Basis of Receptor Recognition by SARS-CoV-2. Nature 581:221–224. https://doi.org/10.1038/s41586-020-2179-y", "volume": "581", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.02.058", "author": "Walls AC", "doi-asserted-by": "publisher", "key": "ref28", "unstructured": "Walls AC et al (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell, vol. 181, no. 2, pp. 281–292.e6. https://doi.org/10.1016/j.cell.2020.02.058", "year": "2020" }, { "DOI": "10.1038/s41586-020-2012-7", "article-title": "A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin", "author": "Zhou P", "doi-asserted-by": "publisher", "first-page": "270", "journal-title": "Nature", "key": "ref29", "unstructured": "Zhou P et al (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature 579:270–273. https://doi.org/10.1038/s41586-020-2012-7", "volume": "579", "year": "2020" }, { "DOI": "10.1038/s41541-020-00246-8", "article-title": "Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in SARS-CoV-2 Spike Protein. npj Vaccines", "author": "McAuley AJ", "doi-asserted-by": "publisher", "first-page": "96", "key": "ref30", "unstructured": "McAuley AJ et al (2020), article no. Experimental and in Silico Evidence Suggests Vaccines Are Unlikely to Be Affected by D614G Mutation in SARS-CoV-2 Spike Protein. npj Vaccines. 5:96. https://doi.org/10.1038/s41541-020-00246-8", "volume": "5", "year": "2020" }, { "DOI": "10.1038/sj.clpt.6100052", "article-title": "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the 'Cocktail' Approach", "author": "Fuhr U", "doi-asserted-by": "publisher", "first-page": "270", "issue": "2", "journal-title": "Clin Pharmacol Ther", "key": "ref31", "unstructured": "Fuhr U et al (2007) Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the 'Cocktail' Approach. Clin Pharmacol Ther 81(2):270–283. https://doi.org/10.1038/sj.clpt.6100052", "volume": "81", "year": "2007" }, { "DOI": "10.1038/s41579-021-00573-0", "article-title": "SARS-CoV-2 Variants, Spike Mutations and Immune Escape", "author": "Harvey WT", "doi-asserted-by": "publisher", "first-page": "409", "journal-title": "Nat Rev Microbiol", "key": "ref32", "unstructured": "Harvey WT et al (2021) SARS-CoV-2 Variants, Spike Mutations and Immune Escape. Nat Rev Microbiol 19:409–424. https://doi.org/10.1038/s41579-021-00573-0", "volume": "19", "year": "2021" }, { "DOI": "10.1038/s41467-022-29219-2", "article-title": "Spike Mutations in SARS-CoV-2 Omicron Variant Modulate Virus Entry and Sensitivity to Neutralizing Antibodies", "author": "Arora P", "doi-asserted-by": "publisher", "first-page": "1620", "journal-title": "Nat Commun", "key": "ref33", "unstructured": "Arora P et al (2022) Spike Mutations in SARS-CoV-2 Omicron Variant Modulate Virus Entry and Sensitivity to Neutralizing Antibodies. Nat Commun 13:1620. https://doi.org/10.1038/s41467-022-29219-2", "volume": "13", "year": "2022" }, { "DOI": "10.3389/fcimb.2021.777378", "article-title": "Emerging SARS-CoV-2 Variants and Their Impact on Spike Glycoprotein-Mediated Viral Entry and Immune Evasion", "author": "Tripathi AK", "doi-asserted-by": "publisher", "first-page": "777378", "journal-title": "Front Cell Infect Microbiol", "key": "ref34", "unstructured": "Tripathi AK et al (2021) Emerging SARS-CoV-2 Variants and Their Impact on Spike Glycoprotein-Mediated Viral Entry and Immune Evasion. Front Cell Infect Microbiol 11:777378. https://doi.org/10.3389/fcimb.2021.777378", "volume": "11", "year": "2021" }, { "DOI": "10.1016/j.cell.2020.12.045", "article-title": "A Systematic Review of Structural and Functional Impacts of SARS-CoV-2 Spike Mutations. Cell", "author": "Singh H", "doi-asserted-by": "publisher", "first-page": "444", "issue": "2", "key": "ref35", "unstructured": "Singh H et al (2021) A Systematic Review of Structural and Functional Impacts of SARS-CoV-2 Spike Mutations. Cell. 184(2):444–456. https://doi.org/10.1016/j.cell.2020.12.045. .e5", "volume": "184", "year": "2021" }, { "DOI": "10.1038/s41598-021-99791-y", "article-title": "The Antioxidant Nrf2 Activator, Sulforaphane, Suppresses SARS-CoV-2 Entry into Human Lung Epithelial Cells. Scientific Reports", "author": "Yamamoto M", "doi-asserted-by": "publisher", "first-page": "20532", "key": "ref36", "unstructured": "Yamamoto M et al (2021), article no. The Antioxidant Nrf2 Activator, Sulforaphane, Suppresses SARS-CoV-2 Entry into Human Lung Epithelial Cells. Scientific Reports. 11:20532. https://doi.org/10.1038/s41598-021-99791-y", "volume": "11", "year": "2021" } ], "reference-count": 36, "references-count": 36, "relation": {}, "resource": { "primary": { "URL": "https://www.researchsquare.com/article/rs-6819274/v1" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "subtype": "preprint", "title": "INP-Guided Network Pharmacology Discloses Multi-Target Therapeutic Strategy Against Cytokine and IgE Storms in the SARS-CoV-2 NB.1.8.1 Variant", "type": "posted-content" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit